POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

Understanding Ghana's FDA and pharmacovigilance regulations

Understanding Zimbabwe's pharmacovigilance system

ASCO 2025: Importance of early testing in metastatic prostate cancer

ASCO 2025: Expert commentary and discussion

ASCO 2025: Highlights and analysis

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC